세계의 전임상 자산 시장 보고서(2025년)

A preclinical asset encompasses all clinical trial supplies or equipment utilized during the preclinical development phase, bridging the gap between drug discovery in the laboratory and the commencement of human clinical trials. This preliminary stage involves essential feasibility assessments, iterative evaluations, and the gathering of safety data, primarily conducted on laboratory animals.

The primary categories of preclinical asset services include bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK studies play a pivotal role in the drug development process, focusing on evaluating the pharmacokinetic and drug metabolism characteristics of potential new drugs. Various models, such as patient-derived organoid (PDO) models and patient-derived xenograft models, are employed by diverse end-users, including biopharmaceutical companies, government institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical assets market size has grown strongly in recent years. It will grow from $5.87 billion in 2024 to $6.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to drug development needs, advancements in biotechnology, regulatory requirements, research funding growth, collaborative research efforts.

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $9.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, ai and machine learning integration, biobanking expansion, focus on rare diseases, government initiatives and funding. Major trends in the forecast period include emergence of advanced imaging techniques, 3d organoid models, multi-omics integration, enhanced predictive models, automation and high throughput screening.

The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. drug development by increasing costs for transgenic animal models and bioreactors imported from China and the Netherlands, potentially slowing research timelines and raising research and development expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising pace of drug discovery is anticipated to boost the growth of the preclinical asset market in the future. Drug discovery is the process of identifying chemical substances that can serve as medicinal agents and involves discovering new candidate medications. Within this framework, preclinical assets play a crucial role by providing essential data and evidence to support the selection of molecules for clinical development as candidates. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical sector, reported significant growth in the European pharmaceutical industry, with production increasing from $352.48 billion in 2021 to $369.95 billion in 2022. Consequently, the increase in drug discovery is driving the growth of the preclinical assets market.

The escalating need to mitigate clinical trial expenditures drives the upward momentum of the preclinical asset market. Clinical trial costs encompass the comprehensive expenses incurred in planning, executing, and managing trials aimed at assessing the safety, efficacy, and potential benefits of novel medical interventions. These trials provide critical insights into the safety, effectiveness, and potential side effects of preclinical assets, validating their therapeutic promise in human subjects. For instance, data sourced from Genetic Engineering and Biotechnology News in February 2023 underscored a substantial rise in the cost of developing new drugs among the top 20 global biopharma companies, soaring by 15% from $298 million in 2022 to approximately $2.3 billion in 2023. This increase encapsulates the expenses incurred throughout the drug development lifecycle, particularly in clinical trial phases. Hence, the mounting emphasis on reducing clinical trial costs propels the expansion of the preclinical asset market.

Product innovation has emerged as a significant trend driving growth within the preclinical assets market. Prominent players in this sector are heavily invested in pioneering new products and solutions to fortify their market position and gain a competitive edge. An illustrative case is the partnership between Charles River Laboratories International and Valo Health Inc. In April 2022, they introduced Logica, an AI-powered drug solution. This innovative offering seamlessly translates biological insights of clients into optimized preclinical assets. By amalgamating Charles River's extensive preclinical expertise with Valo's AI-driven Opal Computational Platform, Logica delivers a unified approach to drug discovery. This transformative partnership ensures the conversion of targets into candidate nominations, enhancing efficiency and yielding highly qualified leads for clients while aligning costs with value creation.

Major companies in the preclinical assets market are concentrating on establishing strategic alliances to enhance their market position. For example, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, a leading research and drug development firm based in India, announced an expanded strategic collaboration aimed at advancing several innovative preclinical and early-stage clinical assets. This partnership builds on the previous collaboration between AbbVie and Scripps Research. Additionally, Calibr will provide AbbVie with a specific number of new discovery targets and preclinical assets of mutual interest for consideration of options.

In October 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation based in the United States, completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for a total of $11.6 billion. Through this acquisition, Pfizer obtained access to a promising portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists, which encompasses Rimegepant, Zavegepant, and a collection of preclinical CGRP assets. Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company headquartered in the United States, known for its early-stage discovery program and various preclinical assets.

Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical Assets Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preclinical assets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preclinical assets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preclinical assets market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies; Toxicology Testing; Compound Management; Safety Pharmacology; Other Services
• 2) By Model Type: Patient Derived Organoid (PDO) Model; Patient Derived Xenograft Model
• 3) By End User: Biopharmaceutical Companies; Government Institutes; Other End-Users
• Subsegments:
• 1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies; Pharmacodynamics (PD) Studies; Bioanalytical Method Development
• 2) By Toxicology Testing: Acute Toxicity Testing; Chronic Toxicity Testing; Genotoxicity Testing; Carcinogenicity Testing
• 3) By Compound Management: Compound Library Management; Sample Storage And Retrieval; High-Throughput Screening Support
• 4) By Safety Pharmacology: Cardiovascular Safety Assessments; Neurotoxicity Evaluations; Respiratory Safety Evaluations
• 5) By Other Services: Regulatory Support; Preclinical Study Design And Consulting; Custom Assay Development
• Companies Mentioned: Laboratory Corporation of America; IQVIA Inc.; ICON PLC; Eurofins Scientific SE; PPD Inc.; SGS SA; WuXi AppTec Co. Ltd.; Intertrek Group PLC; Charles River Laboratories International Inc.; Medpace Inc.; Pharmaron Beijing Co. Ltd.; Evotec SE; GenScript Biotech Corporation; Inotiv Inc.; SRI International Inc.; Shanghai Medicilon Inc.; Biocytogen Pharmaceuticals Beijing Co. Ltd.; AmplifyBio LLC; BioReliance Corporation; Pharmalegacy Laboratories Co. Ltd.; Precigen Inc.; ReproCELL Incorporated; InSphero AG; Crown Bioscience Inc.; Comparative Biosciences Inc.; TCG Lifesciences Pvt. Ltd.; InVivo Biosystems; Pharmatest Services Ltd; Domainex Limited; Viroclinics Xplore
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Preclinical Assets Market Characteristics

3. Preclinical Assets Market Trends And Strategies

4. Preclinical Assets Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Preclinical Assets Growth Analysis And Strategic Analysis Framework

• 5.1. Global Preclinical Assets PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Preclinical Assets Market Growth Rate Analysis
• 5.4. Global Preclinical Assets Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Preclinical Assets Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Preclinical Assets Total Addressable Market (TAM)

6. Preclinical Assets Market Segmentation

• 6.1. Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies
• Toxicology Testing
• Compound Management
• Safety Pharmacology
• Other Services
• 6.2. Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patient Derived Organoid (PDO) Model
• Patient Derived Xenograft Model
• 6.3. Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopharmaceutical Companies
• Government Institutes
• Other End-Users
• 6.4. Global Preclinical Assets Market, Sub-Segmentation Of Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacokinetics (PK) Studies
• Pharmacodynamics (PD) Studies
• Bioanalytical Method Development
• 6.5. Global Preclinical Assets Market, Sub-Segmentation Of Toxicology Testing, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Toxicity Testing
• Chronic Toxicity Testing
• Genotoxicity Testing
• Carcinogenicity Testing
• 6.6. Global Preclinical Assets Market, Sub-Segmentation Of Compound Management, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Compound Library Management
• Sample Storage And Retrieval
• High-Throughput Screening Support
• 6.7. Global Preclinical Assets Market, Sub-Segmentation Of Safety Pharmacology, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Safety Assessments
• Neurotoxicity Evaluations
• Respiratory Safety Evaluations
• 6.8. Global Preclinical Assets Market, Sub-Segmentation Of Other Services, By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regulatory Support
• Preclinical Study Design And Consulting
• Custom Assay Development

7. Preclinical Assets Market Regional And Country Analysis

• 7.1. Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Preclinical Assets Market

• 8.1. Asia-Pacific Preclinical Assets Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Preclinical Assets Market

• 9.1. China Preclinical Assets Market Overview
• 9.2. China Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Preclinical Assets Market

• 10.1. India Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Preclinical Assets Market

• 11.1. Japan Preclinical Assets Market Overview
• 11.2. Japan Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Preclinical Assets Market

• 12.1. Australia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Preclinical Assets Market

• 13.1. Indonesia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Preclinical Assets Market

• 14.1. South Korea Preclinical Assets Market Overview
• 14.2. South Korea Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Preclinical Assets Market

• 15.1. Western Europe Preclinical Assets Market Overview
• 15.2. Western Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Preclinical Assets Market

• 16.1. UK Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Preclinical Assets Market

• 17.1. Germany Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Preclinical Assets Market

• 18.1. France Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Preclinical Assets Market

• 19.1. Italy Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Preclinical Assets Market

• 20.1. Spain Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Preclinical Assets Market

• 21.1. Eastern Europe Preclinical Assets Market Overview
• 21.2. Eastern Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Preclinical Assets Market

• 22.1. Russia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Preclinical Assets Market

• 23.1. North America Preclinical Assets Market Overview
• 23.2. North America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Preclinical Assets Market

• 24.1. USA Preclinical Assets Market Overview
• 24.2. USA Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Preclinical Assets Market

• 25.1. Canada Preclinical Assets Market Overview
• 25.2. Canada Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Preclinical Assets Market

• 26.1. South America Preclinical Assets Market Overview
• 26.2. South America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Preclinical Assets Market

• 27.1. Brazil Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Preclinical Assets Market

• 28.1. Middle East Preclinical Assets Market Overview
• 28.2. Middle East Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Preclinical Assets Market

• 29.1. Africa Preclinical Assets Market Overview
• 29.2. Africa Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Preclinical Assets Market Competitive Landscape And Company Profiles

• 30.1. Preclinical Assets Market Competitive Landscape
• 30.2. Preclinical Assets Market Company Profiles
  • 30.2.1. Laboratory Corporation of America Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. IQVIA Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. ICON PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PPD Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Preclinical Assets Market Other Major And Innovative Companies

• 31.1. SGS SA
• 31.2. WuXi AppTec Co. Ltd.
• 31.3. Intertrek Group PLC
• 31.4. Charles River Laboratories International Inc.
• 31.5. Medpace Inc.
• 31.6. Pharmaron Beijing Co. Ltd.
• 31.7. Evotec SE
• 31.8. GenScript Biotech Corporation
• 31.9. Inotiv Inc.
• 31.10. SRI International Inc.
• 31.11. Shanghai Medicilon Inc.
• 31.12. Biocytogen Pharmaceuticals Beijing Co. Ltd.
• 31.13. AmplifyBio LLC
• 31.14. BioReliance Corporation
• 31.15. Pharmalegacy Laboratories Co. Ltd.

32. Global Preclinical Assets Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Preclinical Assets Market

34. Recent Developments In The Preclinical Assets Market

35. Preclinical Assets Market High Potential Countries, Segments and Strategies

• 35.1 Preclinical Assets Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Preclinical Assets Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Preclinical Assets Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer